Highlights Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Real-time Estimate Cboe BZX Other stock markets 09:27:07 11/09/2024 pm IST			5-day change	1st Jan Change
114.87 ^USD	-1.17%		+6.25%	+84.67%

10/09	Analyst recommendations: Apple, Oracle, Progressive, Dollar Tree...
10/09	Mizuho Boosts Price Target on Vaxcyte to $163 From $113, Maintains Outperform Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mizuho Boosts Price Target on Vaxcyte to $163 From $113, Maintains Outperform Rating	10/09	MT
Health Care Helped By Defensive Bias - Health Care Roundup	07/09	DJ
Vaxcyte Closes $1.5 Billion Offering of Shares, Warrants	07/09	MT
Vaxcyte Prices $1.3 Billion Offering of Shares, Warrants	05/09	MT
Health Care Losses Limited By Vaxcyte's Surge - Health Care Roundup	04/09	DJ
Vaxcyte Starts $1 Billion Underwritten Public Offering	04/09	MT
Sector Update: Health Care Stocks Decline Late Afternoon	04/09	MT
Sector Update: Health Care Stocks Retreat in Afternoon Trading	03/09	MT
Sector Update: Health Care	03/09	MT
Vaxcyte Shares Rise After Plans for Phase 3 Trial of 31-Valent Pneumococcal Conjugate Vaccine Candidate	03/09	MT
Vaxcyte's shares hit record high on early data on pneumococcal vaccine	03/09	RE
Sector Update: Health Care Stocks Lean Lower Pre-Bell Tuesday	03/09	MT
Wall Street Set to Open Shortened Week Lower Tuesday as Investors Await Manufacturing Data	03/09	MT
Sector Update: Health Care	03/09	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of Key Jobs Report	03/09	MT
Vaxcyte Plans Phase 3 Trial for 31-Valent Pneumococcal Conjugate Vaccine Candidate After 'Positive' Phase 1/2 Study Results	03/09	MT
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older	03/09	CI
Vaxcyte, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	07/08	CI
Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants	04/03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Highlights

Filters